‘And Now for Your Entertainment . . . ’

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 1
Volume 7
Issue 1

WASHINGTON-Those were not your ordinary pop bands playing away at the DC Science Writers Association’s annual holiday bash at the National Academy of Sciences building.

WASHINGTON—Those were not your ordinary pop bands playing away at the DC Science Writers Association’s annual holiday bash at the National Academy of Sciences building.

The opening act billed itself as “The Directors.” And, indeed, they were, and all from the National Institutes of Health: Richard D. Klausner, MD, of the National Cancer Institute; Francis S. Collins, MD, PhD, of the National Human Genome Research Institute; and Stephen I. Katz, MD, PhD, of the National Institute of Arthritis and Musculoskeletal and Skin Diseases.

The evening also featured “Wild Type,” a musical ensemble of medical researchers from Johns Hopkins University, led by Bert Vogelstein, MD, professor of oncology. Both bands received a warm reception, but there was general agreement with one guest who suggested to one of the medicomusicians: “Don’t give up your day job.”

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content